One way to enhance the therapeutic potential of antibodies is to
combine, or “conjugate,” them to small molecule drugs, which brings
together the compound’s ability to target a specific antigen and the
potential benefit of a combination drug.
 Another way to enhance
the therapeutic potential of antibodies is to use a technology that
allows the generation of a dual-specific antibody to target two
antigens (also called a dual-variable domain antibody).
Learn more about our pioneering oncology research and development
Turanli-Yildiz B, Alkim C,
Cakar ZP. Protein Engineering Methods and Applications. Protein
Engineering. 2012;ISBN 9789535100379:33-58. Source
of small molecule cancer drugs: Successes, challenges and
opportunities, Mol Oncol, Aprio 2012;6(2):155-176.
B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., &
Walter, P. (2015). Cell death, Molecular biology of the cell (6th
ed.). (pp. 1021-1034). New York, NY: Garland Science.
Cancer Institute FactSheet, Biological Therapies for Cancer:
accessed April 29, 2014.
Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review.
Methods Mol Biol. 2013;1045:1-27.
C. & Fuh, G. Two-in-One antibodies with dual action Fabs.
Current Opinion in Chemical Biology. 2013; 17: 400-405.